Fate Therapeutics (FATE) closed at $1.86 on Oct 19, 2026, up 3.9% on the day. The stock is down 26.5% over the past month, down 34.3% over three months, up 89.8% year to date and up 20.8% over the past year. It trades 42.4% below its 52-week high of $3.23 and 95.8% above its 52-week low of $0.95. The close sits below its 50-day moving average ($2.38) and below its 200-day moving average ($1.91).
NextPick tracks FATE in its Cell / Gene Therapy basket alongside CRSP, BEAM, VCEL, NTLA and PRME. As of Oct 19, 2026, the basket's money-flow score is -18 (weak outflow), and the basket is down 4.8% over five sessions. Over the past month FATE ranks 7th of 7 basket members by price change.
No — the Oct 19, 2026 close of $1.86 is 2.6% below the 200-day average of $1.91.
FATE closed 42.4% below its 52-week high of $3.23.
NextPick groups FATE with CRSP, BEAM, VCEL, NTLA and PRME in its Cell / Gene Therapy basket.
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.
